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Abstract 
 
 
 
Background and aims: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver 
diseases in Western Countries. NAFLD could evolve into nonalcoholic steatohepatitis (NASH), which 
is associated with activation of fibrogenesis, possibly leading to cirrhosis and hepatocellular carcinoma 
(HCC). The genetic background plays a pivotal role in predisposing to development and progression of 
liver disease. Recently, our group have shown that the rs641738 C>T variant, in the Membrane bound 
o-acyltransferase domain-containing 7 locus (MBOAT7), increases the risk of NAFLD, NASH and 
fibrosis, by decreasing the hepatic expression of MBOAT7, a protein involved in phosphatidylinositol 
acyl-chain remodeling. Aim of this study was to evaluate the regulation of hepatic MBOAT7 and the 
impact on hepatic fat accumulation. 
Methods: We examined hepatic and adipose MBOAT7 expression in 119 obese patients and in 
experimental models. We silenced hepatic Mboat7 by i.v. administration of antisense oligonucleotides 
modified by morpholinos (MPO) for 4 consecutive days in C57Bl/6 male mice (n=6). 
Results: In obese patients, hepatic mRNA levels of MBOAT7 progressively decreased from normal 
liver to simple steatosis and NASH (p<0.05). At multivariate analysis, type 2 diabetes (p<0.05), 
necroinflammation (p<0.01) and MBOAT7 genotype (p<0.01) were independently associated with 
MBOAT7 down-regulation. This suggests that down-regulation of hepatic MBOAT7 is involved in 
NAFLD pathogenesis independently of MBOAT7 genotype. In line with this hypothesis, we found that 
mRNA and protein levels of Mboat7 were reduced in experimental models of NAFLD: in the 
methionine-choline deficient diet (MCD), but more so in genetically obese Lep
ob/ob 
mice and in insulin 
resistant mice with Insulin receptor haplo-insufficiency (InsR+/-), characterized by hyperinsulinemia 
(p<0.05). Furthermore, in wild-type male mice Mboat7 was physiologically down-regulated by 
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refeeding concomitantly with the rise of insulin levels and activation of hepatic insulin signaling 
through Phosphatidyl Inositol 3-Kinase (PI3K) and the Serine/Threonine Kinase AKT. In keeping with 
these results, activation of insulin-receptor dependent signaling down-regulated Mboat7 protein 
expression in primary mouse hepatocytes in a PI3Kinase-depedent manner. Consistently, in InsR+/- 
hepatocytes insulin-mediated suppression of Mboat7 was lost (p<0.01). Moreover, the effect of insulin 
on Mboat7 expression was also abrogated in wild-type hepatocytes treated with antisense 
oligonucleotide stabilized by morpholination directed against FoxO1 (MPO) (p<0.05). These data 
suggest that FoxO1 is required to mediate the Mboat7 regulation by insulin. Consistently with this 
notion, the hampered Mboat7 expression observed in InsR+/- hepatocytes was rescued by FoxO1-
silencing by antisense-MPO (p<0.05 vs scramble). Finally, in vivo administration of antisense-MPO 
against Mboat7 for 4 consecutive days, induced a 45% silencing of hepatic Mboat7 in wild-type male 
mice, which is comparable to that associated with the genetic risk variant, resulting in 80% increase in 
hepatic TG content (p<0.05 vs scramble) and in microvesicular steatosis development. In contrast, it 
did not affect circulating glucose, insulin and lipid levels. Steatosis development was not explained by 
altered de novo lipogenesis or β-oxidation or VLDL export, but was associated with increased 
expression of fatty acids transporters (such as Fatp1, Fabp1). Conversely, Mboat7 silencing was not 
associated with alterations in the hepatic expression of inflammatory cytokines and chemokines (such 
as Tnf-α and Cxcl10). These data are consistent with human genetic data suggesting that MBOAT7 
down-regulation plays a causal role in NAFLD development. 
Conclusion: In summary, we found that hyperinsulinemia, a typical feature of metabolic syndrome and 
post-prandial conditions, reduces hepatic MBOAT7 expression via increased insulin signaling 
activation through the Insulin receptor - PI3K – FoxO1 pathway. Reduced MBOAT7 then favors 
hepatic fat accumulation. These data suggest that MBOAT7 down-regulation may be implicated in the 
pathogenesis of progressive NAFLD. 
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1. Introduction 
 
 
1.1 Nonalcoholic fatty liver disease  
 
Nonalcoholic fatty liver disease (NAFLD) is now the most frequent liver disorder worldwide, 
affecting 30% of adults in industrialized countries (1). NAFLD is characterized by hepatic fat 
accumulation that exceeds 5% of liver weight, in absence of alcohol abuse and it is strongly related to 
visceral obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) (2, 3). Indeed, 
NAFLD is regarded as the hepatic manifestation of MetS and its prevalence increases with body mass 
index (BMI), reaching 60-70% in obese patients (4).  
NAFLD defines a wide spectrum of liver diseases, ranging from simple and uncomplicated 
steatosis to the progressive form, namely nonalcoholic steatohepatitis (NASH; 2-3% of general 
population), which is characterize by hepatocyte ballooning, lobular necroinflammation, enhanced 
oxidative stress, mitochondrial dysfunction and liver fibrosis and that could evolve into cirrhosis and 
hepatocellular carcinoma (HCC) in susceptible individuals. Notably, hepatic fat accumulation and 
NASH have been recognized as risk factors for cirrhosis, liver failure and HCC, that is the third most 
common cause of cancer death (5). The risk of developing the progressive form of the disease is higher 
in patients with severe insulin resistance (IR) and T2DM, that are considered the strongest predictors of 
the progression of NAFLD to advanced fibrosis and cirrhosis. Indeed, the prevalence of NAFLD in 
T2DM patients is estimated at 34-74% and it is even higher in T2DM patients with obesity (100%) (6).  
To date, there are no approved drugs for the treatment of NAFLD and lifestyle intervention with 
a focus on healthy eating, weight loss and regular exercise remain the mainstay in the management of 
patient with NAFLD. Indeed, effective and sustained weight loss has been associated with marked 
improvement in glycemic control, hepatic insulin sensitivity, liver enzymes and liver histology (7). 
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Fig. 1: The spectrum of NAFLD. The accumulation of TG within lipid droplets in hepatocytes causes steatosis. 
Steatosis associated with inflammation, cell death, and fibrosis is referred to as NASH, which can progress to 
cirrhosis. Individuals with cirrhosis have an increased risk of HCC. Modified from Cohen C. et al, Science 2011 
(8). 
 
1.2 Insulin resistance and NAFLD pathogenesis  
 
Although the exact mechanism of NAFLD pathogenesis is still not completely understood, 
current knowledge supports a model whereby development of liver damage is multifactorial, 
commonly summarized to as the ‘multi-hit’ hypothesis (9-12). The ‘first hit’ causes the rising of 
hepatic steatosis due to IR.  
Mammals have complex mechanisms to maintain energy homeostasis during periods of 
nutritional abundance and starvation. The nutritional state of an organism is reflected by the circulating 
levels of the two pancreatic hormones insulin and glucagon, which elicit regulatory responses in the 
peripheral tissues (adipose tissue and muscle). Liver acts as a ‘metabolic integrator’, by regulating 
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glycogen degradation, gluconeogenesis, fatty acids oxidation and ketogenesis, thereby maintaining 
normo-glycemia and ensuring constant energy supply to glucose-dependent tissues, such as the brain. 
Following food intake, plasma insulin levels rise and suppress hepatic glucose production, β-oxidation 
and ketogenesis and instruct the liver to convert glucose to glycogen for storage and promote TG 
synthesis (13). In hepatocytes, metabolic responses to changes in plasma insulin levels are mediated at 
intracellular levels by the insulin/phosphatidylinositol-3-kinases (PI3K)/Akt signaling cascade. 
Downstream targets of the Akt kinases are glycogen synthase kinase 3 (GSK3), mammalian target of 
rapamycin (mTOR) and several members of the Forkhead box transcription factors (14), such as 
Forkhead box protein O1 (FoxO1), an activator of rate-limiting gluconeogenic enzymes (15) and 
FoxA2, a key regulator of hepatic lipid metabolism, that is transcriptionally active in the fasted state 
(16-18). 
 
Fig. 2: The insulin signaling pathway in hepatocytes. Insulin binding to its receptor (INSR) leads to auto-
phosphorylation of the insulin-receptor substrates (IRS1 and 2), activation of PI3K and subsequent 
phosphorylation of Akt 1/2. Activation of protein kinase Akt 1/2 mediates the metabolic effects of insulin 
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promoting glycogen and protein synthesis, through GSK3 and mTOR and inactivating the transcription factors 
FoxO1, which in absence of insulin induces gluconeogenesis, lipoprotein export and apoptosis and FoxA2, 
involved in fatty acids oxidation and ketogenesis. Phosphorylation of these two transcription factors in response 
to Akt 1/2 activation leads to their nuclear exclusion, ubiquitination and proteasomal degradation (19). Modified 
from Dongiovanni P. et al, Expert Review of Gastroenterology and Hepatology 2016 (20). 
 
In peripheral metabolic tissues, muscle and fat, insulin stimulates dietary glucose uptake by 
driving the translocation of glucose transporters GLUT-4 to the cell surface and promotes fat storage 
through induction of lipoprotein lipase and lipogenesis. 
 
IR is defined as a clinical condition where normal or elevated insulin levels produce an 
attenuated biological response, particularly in terms of glucose homeostasis (21). IR may be caused 
directly from altered insulin receptor activity or by alteration in the downstream signaling pathways. It 
is rarely determined by loss-of-function mutation in INSR gene, but most frequently reflects reduced 
expression on the cellular membrane. In obesity, IR is described by hyperinsulinemia by decreasing 
insulin clearance, increased glucose output and decreased glucose utilization of the liver. Indeed, in 
order to compensate the impaired insulin response, the pancreatic β-cells increase insulin production, 
eventually undergoing exhaustion and leading to impaired glucose tolerance and T2DM (22). In 
particular, in IR conditions, insulin fails to inactivate FoxO1 further inducing hepatic glucose output 
(23). Conversely, the hepatic regulation of FoxA2 phosphorylation by insulin-stimulated IRS signaling 
is not impaired in hyperinsulinemia or IR states, where FoxA2 is found exclusively in the cytoplasm of 
hepatocytes, despite the defect in hepatic insulin signaling (17, 24). This difference can be explained by 
the preferential phosphorylation of FoxO1 through insulin–IRS2 signaling, which is impaired in 
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hepatic IR, whereas FoxA2 can be phosphorylated by either insulin–IRS1 or insulin–IRS2 signaling 
(17).  
In muscle and adipose tissue, IR determines an impairment of glucose uptake and promotes an 
enhanced activity of hormone-sensitive lipoprotein lipases, favoring lipid storage dismissal. 
Thus, in NAFLD patients, hepatic fat accumulation results from an increased efflux of non-
esterified or free fatty acids (FFAs) from adipose tissue to the liver (25). FFAs which derive from 
peripheral lipolysis related to adipose tissue IR (26) are stored into the hepatocytes as triglycerides 
(TG), in order to protect hepatocytes themselves from lipotoxicity (25). Furthermore, hyperinsulinemia 
activate also lipogenic transcription factors, such as sterol regulatory element-binding protein-1c 
(SREBP-1c) and induce de novo lipogenesis from glucose, exacerbating hepatic fat deposition. 
Reduction in neutral lipid secretion through very low-density lipoproteins (VLDL) (27) and in β-
oxidation due to mitochondrial damage are also involved in steatosis exacerbation. Thus, the hepatic fat 
accumulation derives from an unbalance between TG acquisition, synthesis and removal (8). Viceversa, 
fatty liver per se may then precipitate hepatic IR promoting metabolic disturbances and cardiovascular 
damage (28, 29). Indeed, excess of intracellular storage of lipid metabolites, such as diacylglycerol, 
ceramides and long chain acyl CoA, has also been implicated as a mediator of IR, triggering the 
activation of c-Jun N terminal kinase (JNK), affecting insulin signaling (30).  
 
1.3 Evolution to NASH  
 
The progression of steatosis to NASH is currently explained by the occurrence of multiple 
parallel hits in the background of fatty liver. These insults are represented by a) direct hepatic 
lipotoxicity due to toxic lipid metabolites; b) hepatocellular oxidative stress secondary to free radicals 
produced during β- and ω- oxidation of FFAs and subsequent activation of stress related signaling 
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pathways; c) inflammation triggered by endotoxin engaging TLR-4 receptors in Kupffer cells, 
(macrophages localized into the sinusoids) and in hepatocytes due to increased intestinal permeability 
and altered intestinal flora (31, 32); d) qualitative and quantitative changes in the gut microbiota; e) 
pro-inflammatory cytokines and chemokines release (33) and f) injury occurring to intracellular 
organelles (endoplasmic reticulum (ER) stress and mitochondrial disfunction). These injuries also 
trigger to fibrogenesis and progression to cirrhosis. In fact, cytokines and chemokines are involved in 
the recruitment and activation of Kupffer cells and in the transformation of hepatic stellate cells (HSCs) 
into myofibroblasts, both involved in the progression from steatosis to NASH (34).  
Visceral obesity also contributes to NASH development as well as IR. Several adipokines are 
released by white adipose tissue (WAT), such as adiponectin, leptin, resistin, TNF-α, IL-1β, IL-6 (9). 
These adipokines down-regulate glucose transporter GLUT-4 expression via increased serine 
phosphorylation of IRS-1 (14) and affect insulin signaling, inducing IR (35). 
The worsening of liver damage is marked by accumulation of hepatic fibrosis resulting from 
deposition of extra-cellular matrix (ECM) preferentially in perisinusoidal/pericellular spaces, due to the 
activation of HSCs. HSCs are localized in sinusoids adjacent to the hepatocytes; they are generally 
quiescent and characterized by the presence of retinol droplets in the cytoplasm. When activated by 
hepatotoxic insults, HSCs acquire the ability to proliferate, contract themselves and migrate, produce 
cytokines and chemokines, release retinols and secrete collagen and ECM, perpetuating the 
inflammation and fibrosis. In NASH patients, collagen fibers are mainly localized around the 
hepatocytes, hesitating in perisinusoidal/pericellular (“chicken wire”) fibrosis, which spreads into the 
parenchyma. Hyperinsulinemia and hyperglycemia stimulate HSCs to produce ECM. IR correlates with 
the severity of liver fibrosis, reducing ECM degradation and favoring collagen cross-linking, and 
fibrosis progression is observed in T2D patients with NAFLD (36). Moreover, functional common 
genetic variants of molecules involved in insulin signaling have been associated with the severity of 
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liver damage (37). There is a strong correlation between IR severity and the development of NASH, but 
it is still unknown to what extent IR is cause or consequence of liver damage, and the precise molecular 
mechanism underlying the association (38).  
Activated HSCs could have two different fates: apoptosis or senescence. About half of activated 
HSCs escape apoptosis. They down-regulate fibrogenic genes, but they could be easily reactivated, in 
response to recurring fibrogenic stimuli (39). Cellular senescence of persistent HSCs in response to 
chronic inflammation contributes to the pathogenesis of HCC in NASH subjects. Indeed, senescence is 
linked to gene expression alterations, including a program known as the senescence-associated 
secretory phenotype (SASP) (40). In this program, a large amount of cytokines, chemokines and 
proteases secreted from senescent cells promote crosstalk with other cells in the microenvironment. 
Some of SASP factors have a positive function in resolution of liver damage, promoting cell-cycle 
arrest or selective apoptosis of activated HSCs, through immune cells recruitment. Others factors, 
instead, are associated with inflammation and tumorigenesis promotion (as IL-1β, IL-6, CXCL1, 
CXCL9 and PAI-1) (41).  
 
1.4 Genetic predisposition in NAFLD and NASH  
 
Although obesity and IR are the most prevalent risk factors for NAFLD, hepatic fat content 
varies substantially among individuals with equivalent adiposity, indicating that other factors contribute 
to this condition. Indeed, epidemiological, familial, and twin studies provide evidence of a strong 
heritability of hepatic fat content and there is a huge inter-ethnic variability in the predisposition 
towards NAFLD (42, 43). Two large multi-ethnic population studies conducted in the US detect higher 
risk of NAFLD in Hispanics than individuals of European descent, whereas African-Americans are 
14 
 
protected irrespectively of diabetes, excess in body weight and socioeconomic factors, consistent with a 
key role of heritability (44). 
Several genetic risk factors are recognized to influence the onset and the severity of NAFLD. 
To date, the major genetic determinant of inter-individual and ethnicity-related differences in hepatic 
fat content and the major predictor of predisposition to progressive NAFLD, is the rs738409 C>G 
variant of the Patatin-like Phospholipase domain containing 3 gene (PNPLA3 or adiponutrin), 
encoding for the amino acid substitution Isoleucine to Methionine at the position 148 (referred to as 
I148M) (45). The M risk allele is more prevalent in Hispanics than in Europeans and less frequent in 
African Americans, possibly explaining the inter-ethnic susceptibility to NAFLD. PNPLA3 is a 
intracellular membrane lipase, localized in the endoplasmic reticulum and at the surface of lipid 
droplets, in hepatocytes, adipocytes, and in HSCs. In particular, it is involved in lipid remodeling on 
lipid droplet surface, retinol metabolism and retinol release by HSCs (46, 47). The I148M variant has a 
strong impact on the full spectrum of liver damage related to fatty liver, encompassing NASH, 
advanced fibrosis, and HCC, and influences the response to therapeutic approaches (48). The 
mechanism of steatosis development is related to accumulation of the mutated protein on the lipid 
droplet surface, thus, interfering with lipid remodeling in fatty-laden hepatocytes and inhibiting the 
activity of other lipases and accordingly, reducing TG turnover and dismissal. The accumulation of the 
I148M mutated protein seems to be due to the less accessibility to ubiquitin ligases and to impaired 
proteasomal degradation (49, 50). In HSCs, instead, PNPLA3 I148M variant alters retinol secretion, 
potentially contributing directly to fibrogenesis and carcinogenesis, increasing the risk in cirrhosis and 
HCC development, independently of the predisposition to steatosis (51-53). The size effect of the 
I148M variant on the risk of NAFLD is the strongest ever reported for a common variant, modifying 
the genetic susceptibility of NAFLD and liver disease progression. 
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The low-frequency rs58542926 C>T variant of Transmembrane 6 superfamily member 2 gene 
(TM6SF2), encoding for the loss-of-function E167K substitution also predisposes to progressive 
NAFLD by altering the secretion of VLDL. This is associated with hepatic fat content, 
aminotransferases concentration and lower serum lipoproteins. The mechanism is related to retention of 
lipids within intracellular lipid droplets resulting in steatosis. Conversely, by reducing circulating 
lipids, the E167K variant decreases the risk of cardiovascular events (54, 55). 
The common loss-of-function polymorphism (rs1260326) in the Glucokinase regulatory 
(GCKR) gene, encoding for the P446L substitution has been also associated with increased fasting TG 
levels, hepatic fat accumulation and liver damage. GCKR regulates DNL by controlling the influx of 
glucose into the hepatocytes and the P446L variant affects GCKR ability to negatively regulate 
glucokinase, determining a constitutive activation of hepatic glucose uptake. This leads to decreased 
circulating fasting glucose and insulin levels, favoring, in turn, glycolysis and steatosis onset by 
providing malonyl-CoA as substrate for DNL and by blocking fatty acid oxidation (56-58). 
 
1.5 The MBOAT7 rs641738 variant is novel a risk factor for NAFLD 
onset and progression 
 
 Recently, the first genome-wide association study (GWAS) screening the determinants of 
alcoholic cirrhosis in heavy drinkers, led to the identification of the common variant rs641738 C>T 
(population prevalence of 58-67%), a single nucleotide polymorphism in the Membrane bound o-
acyltransferase domain-containing 7 – Transmembrane channel-like 4 (MBOAT7-TMC4) as a 
susceptibility locus on chromosome 19 (59). Most importantly, we have shown that this variant 
associates with steatosis severity and the entire spectrum of liver damage related to NAFLD, 
particularly in terms of necroinflammation and more advanced fibrosis (60, 61). The impact of this 
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variant on hepatic fat accumulation and metabolism has been demonstrated in two different 
independent cohorts of individuals: the Dallas heart study (DHS) cohort and the Liver biopsy cross-
sectional cohort. The DHS cohort is a population study that includes 3854 individuals, of whom 2736 
underwent to proton magnetic resonance spectroscopy to measure hepatic TG content. The Liver 
biopsy cross-sectional cohort (LBC), instead, comprehends 1149 European subjects, who underwent to 
liver biopsy for suspected NASH or severe obesity. Patients carrying T allele show an enhanced 
intrahepatic TG content in these two independent cohorts and a higher prevalence of NASH and 
fibrosis in the LBC cohort, compared with non-carriers (60). Furthermore, children carrying the T 
allele of MBOAT7 have higher plasma ALT levels, C-reactive protein (CRP) concentration and body 
fat percentage than the non-carriers (62). 
 In addition, the MBOAT7 variant has been recognize also as a risk factor for HCC 
predisposition, in patients without cirrhosis. In fact, in 765 Italian NAFLD patients without advanced 
fibrosis, it has been associated with NAFLD evolution to HCC (63). Nonetheless, the rs641738 variant 
has been identified as a risk factor for liver damage progression, in particular in the transition to early 
fibrosis, even in viral hepatitis C (HCV) and B (HBV) (64, 65). Finally, in 1121 non-cirrhotic patients 
with HCV or alcoholic liver disease, the T allele has been independently associated with HCC risk. The 
effect of this variant on HCC risk disappears with disease progression and it has no effect on the late 
stages of fibrosis (63). 
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Fig. 3: The rs641738 variant is associated with increased intrahepatic TG content in the DHS cohort and with 
the severity of histologic damage in the Liver Biopsy Cross-Sectional Cohort. The association between TG 
content and T allele presence has been tested by linear regression analysis adjusted for age, sex, ethnicity, BMI, 
IFG/T2DM, PNPLA3 I148M, and TM6SF2 E167K genotype, and data are shown as median value. Numbers in 
brackets represent interquartile range. P value represents the significance of a linear trend in median trait value 
among genotypes. The association between the rs641738 variant and NASH prevalence has been tested by 
multivariate ordinal regression analysis adjusted for age, sex, BMI, presence of IFG/T2DM, number of PNPLA3 
I148M alleles, presence of the TM6SF2 E167K variant, and indication of liver biopsy (severe obesity vs 
nonalcoholic fatty liver with increased liver enzymes). P values represent the significance of a trend in the 
prevalence of NASH among genotypes. Genetic analyses have been performed by using an additive model. CC, 
homozygotes for the C allele; CT, heterozygotes; TT, homozygotes for the T allele. 
 
1.6 MBOAT7 function and pathogenic effect of the rs641738 variant  
 
MBOAT7 is the mammalian orthologue of mboa-7, that has been previously identified by using 
a RNA interference–based genetic screen in Caenorhabditis elegans (66). mboa-7 deletion mutants 
showed a decrease in the content of Eicosapentaenoic acid (EPA), the predominant polyunsaturated 
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fatty acid (PUFA) in C. elegans, in phosphatidylinositol (PI) amount (66) and impaired PI-3-phosphate 
(PI3P)-related events such as early endosome morphology and autophagy (67).  
MBOAT7 is also known as lysophosphatidylinositol acyltransferase 1 (LPIAT1). It codifies for 
an enzyme, member of the “Lands’ Cycle” of phospholipid acyl-chain remodeling of the membranes, 
through sequential deacylation and reacylation reactions. It catalyzes a desaturation of the second acyl-
chain of phospholipids and specifically transfers a PUFA, in form of acyl-CoA to 
lysophosphatidylinositols (lysoPI) and other lysophospholipids, using as preferential substrate the 
arachidonoyl-CoA. Thus, it regulates the amount of free arachidonic acid, a potent trigger for liver 
inflammation and fibrosis, that is also the precursor of the main proinflammatory mediators 
(Eicosanoids) (68). Indeed, MBOAT7 activation has been associated with anti-inflammatory processes 
by limiting the availability of free arachidonic acid in Leukotriene B4 synthesis in neutrophils, that is a 
strong chemoattractant mediator (69). Furthermore, it may also influence signal transduction pathways 
and the fluidity and the dynamism of cell membranes, essential for membrane fusion and fission steps 
during endocytosis, exocytosis, cytokinesis and vesicle trafficking. 
Mboat7 plays a crucial role in brain development in mice, since arachidonic acid is the most 
enriched PUFA in the brain and it is involved in multiple aspects of neuronal development and 
function. Mboat7 knock-out (KO) mice show almost no activity with arachidonoyl-CoA as an acyl 
donor and show reduced arachidonic acid contents in PI and PI phosphates (PIP, PIP2 and PI3P). PI are 
lipids, which regulate membrane dynamics and signal transduction pathways, whereas PI phosphates 
are synthesized by PI kinases and phosphatases and play crucial roles in the regulation of a wide 
variety of cellular processes via specific interactions of PIP-binding proteins (70, 71). Among PI 
phosphates, PI 3-phosphate (PI3P) regulates a variety of vesicular trafficking pathways, including 
endocytosis, endosome-to-Golgi retrograde transport, autophagy and mTOR signaling pathway (72). PI 
consist of a glycerol backbone and two variable fatty acyl-chains, one of which is predominantly 
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saturated and the other polyunsaturated. Specifically, arachidonic acid-containing PI/PI phosphates 
play an important role in normal cortical lamination during brain development in mice. Indeed, Mboat7 
KO mice die within a month and show atrophy of the cerebral cortex and hippocampus, disordered 
cortical lamination and neuronal processes and delayed neuronal migration in the cortex (67, 73). 
Notably, inactivating variants in MBOAT7 lead to intellectual disability accompanied by epilepsy and 
autistic features in patients (74, 75). 
At a cellular level, MBOAT7 is highly expressed in human hepatocytes, sinusoidal endothelial 
cells, immune cell subsets and HSCs. It is localized specifically in membrane fractions rich in 
phospholipids, such as the ER and the mitochondria-associated membranes (MAM), where arachidonic 
acid-selective acyl-CoA synthases are enriched (60). MAM is a membrane bridge between the ER and 
mitochondria, that is involved in the biosynthesis and trafficking of lipids between the two organelles 
(76, 77) and in lipid droplets formation (78). It interacts with the small subunit of serine 
palmitoyltransferase a (ssSPTa), that plays a role in fatty acid remodeling of PI, probably by facilitating 
the MAM localization of MBOAT7 (79).  
 
Another enzyme of the MBOAT family, MBOAT5, also named Lysophosphatidylcholine 
acyltransferase 3 (LPCAT3), has similar enzymatic activity to MBOAT7. It is ubiquitously expressed, 
especially in liver, testis, kidney, pancreas and adipose tissue, where it participates in the acyl-chain 
remodeling of Phosphatidylcholines (PC), Phosphatidylserine (PS) and Phosphatidylethanolamines 
(PE) (80). Expression of LPCAT3 mRNA is controlled by liver X receptors (LXR) and is induced 
during adipogenesis (81). Mboat5 KO mice are neonatally lethal due to an extensive TG accumulation 
in enterocytes, because TG are not assembled into lipoproteins. Mice with specific deletion of hepatic 
Mboat5 display a decreased arachidonic acid-containing PC, PS and PE in the liver and an increased 
risk of hepatic steatosis onset, due to altered lipid kinetics within hepatocytes, and inflammation (82, 
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83). Conversely, the induction of Mboat5 ameliorates saturated free fatty acid-induced ER stress, 
lowering also blood glucose and insulin levels in Lep
ob/ob 
mice (81, 84). 
MBOAT5 and MBOAT7 are both susceptible to inhibition by Thimerosal, a thiol-reactive 
reagent. 
 
 
Fig. 4: Integrated model for the Land’s cycle of phospholipids remodeling of the membranes and arachidonic 
acid mobilization.  
The major phospholipids in the membranes are Phosphatidylcholines (PC), Phosphatidylserine (PS), 
Phosphatidylethanolamines (PE) and Phosphatidylinositols (PI). Arachidonic acid in the sn-2 position of these 
membrane lipids is released by the action of Phospholipase A2 (cPLA2), generating the corresponding 
lysophospholipids and free arachidonic acid. This can then be used for the production of various 
proinflammatory Eicosanoids or can be returned to the phospholipid pool via the action of an acyl-CoA ligase 
and either MBOAT7 (that uses lyso-PI) or MBOAT5 (that uses lyso-PC, lyso-PS, and lyso-PE). Thimerosal, an 
MBOAT inhibitor, increases the production of Eicosanoids (Prostaglandins and Leukotrienes). 
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The pathogenic effect of the rs641738 variant is probably due to the dampened gene and protein 
expression of MBOAT7 in the liver of patients carrying T allele. In line with these results, these 
patients also display changes in plasma and hepatic PI species, specifically a decrease in PI enriched in 
omega-3 PUFA and arachidonic acid, consistently with decreased hepatic MBOAT7 total activity (60, 
61). The risk T allele is associated with a PI composition pattern suggestive of lower levels of 
arachidonoyl-PI/total PI (PI containing polyunsaturated fatty acid chains) and with higher levels of 
oleyl-PI/total PI linoleoyl-Pl/total PI ratios (PI containing saturated and monounsaturated fatty acid 
chains). These data are consistent also with the changes found in liver PI levels of MBOAT7 KO mice, 
suggesting that reduced enzymatic activity of MBOAT7 may explain the increased liver fat 
accumulation and progressive liver damage, in T allele carriers. However, to date it is not known 
whether rs641738 causes the decreased expression of MBOAT7 or whether the observed reduction in 
both mRNA and protein synthesis is due to linkage disequilibrium between rs641738 and variants in 
the 3’UTR of MBOAT7 (eg, rs8736 C>T, R2 > 0.95 in the CEU population from the 1000 genomes 
project), which may influence mRNA stability/translation. Specifically, in severely obese patients, the 
rs641738 variant is in high linkage with the MBOAT7 3′UTR variant rs8736 polymorphism (R2 = 0.98; 
only 1/98 discordant case). The rs8736 polymorphism is non-significantly more closely associated with 
NAFLD and MBOAT7 expression than rs641738, suggesting that rs641738 is not the causal variant, 
but may be in linkage with variants influencing MBOAT7 expression (63).  
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Fig. 5: The rs641738 variant decreases MBOAT7 mRNA expression and synthesis level in liver biopsies of obese 
patients. The rs641738 hepatic mRNA levels of MBOAT7 in 98 severely obese patients are stratified by the 
presence of the rs643718 C>T genotype and data are expressed as fold increase as compared with the protective 
CC genotype. Western blotting analysis and quantification, instead, represents MBOAT7 protein levels of 7 
samples of obese patients for each rs641738 genotype. Data are expressed as fold increase of the 3 MBOAT7 
isoforms 1-3 (molecular weight: 52 kDa, 44 kDa, and 38 kDa), as compared with the protective CC genotype. P 
< .005 (additive model; it represents the difference in the traits examined across MBOAT7 genotypes). 
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2. Aims 
 
 
Nonalcoholic fatty liver disease (NAFLD) is now the most frequent liver disorder worldwide, 
affecting around 30% of adults in industrialized countries (1). The rs641738 C>T variant in the 
membrane-bound O-acyltransferase domain-containing protein 7 (MBOAT7) gene has been recently 
found to be associated with increased risk of developing steatosis and progressive form of NAFLD in 
adults. MBOAT7, also known as lysophosphatidylinositol acyltransferase 1 (LPIAT1), is an enzyme 
that is expressed in the liver and is involved in the reacylation of phospholipids as part of the 
phospholipid remodeling pathway ‘Land’s cycle’ by specifically transferring polyunsaturated acyl-
CoAs, such as arachidonoyl-CoA, to lysophosphatidylinositol and other lysophospholipids. The 
carriers of the T allele of the MBOAT7 polymorphism were found to have reduced expression and 
synthesis of the MBOAT7 protein in the liver and changes in plasma phosphatidylinositol species 
consistent with decreased MBOAT7 function (60, 61). These observations suggest that reduced 
enzymatic activity of MBOAT7 may explain, on one side, the increased liver fat accumulation and the 
steatosis onset, and, on the other side, the liver damage worsening into NASH and advance fibrosis, in 
T allele carriers.  
Our hypothesis is that the blunted expression of MBOAT7 due to the genetic background and 
insulin resistance plays a causal role in the development and progression of NAFLD. Indeed, higher 
levels of circulating bioactive proinflammatory metabolites of arachidonic acid have been reported in 
patients with NASH. 
Thus, the aims of this study were  
1) To examine the clinical and genetic determinants of hepatic MBOAT7 expression in 
patients at risk of NASH and the association with liver damage. To this end, we evaluated 
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the hepatic and adipose tissue MBOAT7 expression in 119 Italian severely obese patients at 
risk of NASH, who underwent liver biopsy during bariatric surgery.  
2) As we detected a strong link between Mboat7 down-regulation and hyperinsulinemia 
associated with insulin resistance, to investigate in vivo and ex vivo in primary mouse 
hepatocytes and cell lines the mechanisms by which insulin signaling regulated MBOAT7 
expression during physiological conditions and in dietary and genetics models of NAFLD.  
3) To test the causative role of Mboat7 down-regulation in NAFLD development in 
experimental models, confirming data from genetic epidemiological studies. To this end, we silenced 
hepatic Mboat7 in wild-type mice in vivo, by i.v. administration of antisense oligonucleotides modified 
by morpholinos (MPO), and evaluated the impact on hepatic fat content and metabolism and 
inflammation.  
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3. Material and methods 
 
 
3.1 Chemicals 
 
Methionine and Choline deficient diet (MCD) was purchased from Test Diet (London, UK); 
insulin Insuman Rapid (0.75 U/Kg) was ordered from Sanofi Aventis (Milan, Italy). Anti β-Actin was 
acquired from St. Cruz Biotechnologies (Santa Cruz, United States); anti P-Thr308 Akt, Akt, FoxO1, 
P(T389)-P70S6, Rapamycin and Akt inhibitor (LY294002) were purchased from Cell Signaling 
Technologies (Boston, United States); anti Foxa2 and anti Histone H3 antibodies were purchased from 
Abcam (Cambridge, UK); anti-MBOAT7 from Sigma-Aldrich. Dulbecco’s modified Eagle’s medium 
(DMEM), fetal bovine serum (FBS), phosphate-buffered saline (PBS), L-Glutamine, 
Penicillin/Streptomycin, Trypsin/EDTA and Hank’s balanced salt solution (HBSS) were obtained from 
Gibco-ThermoFisher scientific (Waltham, United States). Fast SYBR green master mix was obtained 
from Life Technologies-ThermoFisher Scientific (Waltham, United States). Collagenase type IV from 
Clostridium Histolyticum, Pronase E from Streptomyces Griseus, DNAse I from bovine pancreas, 
Optiprep density gradient media and fructose were purchased from Sigma-Aldrich (St. Louis, United 
States). Clarity western ECL substrate was obtained from Bio-Rad Laboratories (Hercules, United 
States). Free fatty acids (FFAs) Quantification Kit, Triglyceride Quantification Kit was purchased from 
BioVision (Milpitas, United States). Rat/Mouse Insulin ELISA kit (Millipore, United States) was 
bought from Merck Millipore (Billerica, United States).  
 
3.2 Experimental models  
 
C57Bl/6 mice (Charles River, Calco, Italy) were housed at constant room temperature (23°C) 
under 12-hour light/dark cycles with ad libitum access to water in compliance with the Principles of 
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Laboratory Animal Care (NIH publication 86-23). InsR+/- mice on C57Bl/6 background were kindly 
provided by Prof. Accili D, Columbia University, NY, USA (85). Genotyping was performed using 
genomic DNA extracted from mouse tail (86). C57Bl/6 Lep
ob/ob
 mice were purchased from Charles 
Rivers (Calco, Italy). 
To induce NASH, wild-type and InsR+/- male mice, which are more susceptible to develop 
liver damage and fibrosis compared to female, were fed either MCD (Methionine Choline deficient 
diet, 14.8% protein, 12.4% fat and 72.8% carbohydrates, Test Diet, London, UK) or regular chow 
(15.1% protein, 12.4% fat and 72.4% carbohydrates Test Diet, London, UK) for 6 weeks, starting from 
6 weeks of age. Experiments were conducted in 10 mice per group. In a second set of experiments, 
supplemental fructose was administered as 30% fructose in drinking water. Body weight was recorded 
weekly throughout the experiments. Before sacrifice, mice were fasted for 16 hours and the 
interventions were done during the light cycle. 
In another experimental setting, in order to study the physiological alteration of Mboat7 due to 
the nutritional state, wild-type male mice of 6 weeks of age were fasted for 16 hours and then refed for 
different time point (15 minutes, 1 hours, 4 hours or 8 hours). Experiments were conducted in 7 mice 
per group per each time point, unless otherwise specified.  
The experimental protocol was approved by University of Milan and Italian Ministry of Health 
Review Boards (protocol 8/14).  
 
3.3 Samples collection and biochemical evaluation 
 
Blood samples were collected by tail vein puncture. Blood glucose was measured by an Accu-
Check glucometer (Roche Diagnostics AVIVA, Mannheim, Germany) and fasting plasma insulin 
levels by ELISA (EZRMI-13K, Millipore, Billerica, MA). Plasma and hepatic triglycerides, total 
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cholesterol and alanine aminotransferase (ALT) levels were measured with an automated analyzer 
(CobasC 702, Roche, Switzerland). Circulating free fatty acids (FFAs) were measured by a 
colorimetric assay (BioVision, Milpitas, United States) according to the manufacturer’s instructions. At 
sacrifice, liver, proximal intestine and visceral adipose tissue (VAT) samples were rapidly removed, 
harvested and snap frozen in liquid nitrogen. Samples of liver were fixed in 10% PBS buffered 
formalin and embedded in paraffin within 24 hours of formalin fixation, for histological evaluation. 
Tissue sections were stained by Hematoxylin and Eosin (H&E) to assess liver pathology, according to 
Kleiner et al (87). 
 
3.4 Gene silencing 
 
To silence ex vivo FoxO1 and/or Foxa2, key mediators of insulin signaling at transcriptional 
level, we exploited Morpholino antisense oligonucleotides (MPO) specifically targeting FoxO1 and/or 
Foxa2 by blocking translational initiation and the in vivo “Standard control”, whose sequences were 5’-
CCACCAGCAGAGAAGTACCGGGAGA-3’, 5’-TCCATCTTCACGGCTCCCAGCATAC-3’ and 5’-
CCTCTTACCTCAGTTACAATTTATA-3’ respectively (Gene tools, www.gene-tools.com). Primary 
mouse hepatocytes were incubated with FoxO1 and/or Foxa2-specific MPO or scramble (10 μM) for 
24 hours in medium 0.5% BSA. Moreover, InsR+/- mice were treated with 12.5 mg/kg of FoxO1-
specific MPO or scramble administered i.v. once a week during 3 weeks of MCD feeding (n=5 per 
group). 
To silence in vivo Mboat7 wild-type mice were treated with 12.5 mg/kg of MBOAT7-specific 
MPO or scramble administered i.v. daily for 4 days (n=6 per group). MBOAT7-specific MPO sequence 
was 5’-ATATGTCCATTCTTCGGGTGTCAT-3’. 24 hours after the last injection, mice were 
sacrificed.  
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3.5 Isolation of hepatic cells 
 
Human hepatocytes and hepatic stellate cells (hHSC) were isolated from non-neoplastic tissue 
obtained from explanted or resected livers of 17 patients. All samples were negative for hepatitis B 
virus surface antigen (HBsAg) and for hepatitis C virus (HCV)-RNA. Samples from all-aged donors 
with variable steatosis and fibrosis grade were included in the study. Informed written consent of each 
patient were obtained, according to legal and ethical rules established by the Ethics Committee of the 
Fondazione IRCCS Cà Granda, which has already approved the protocol. Liver tissue were stored in a 
Celsior preservation solution for a maximum of 8 hours from the explantation, at 4°C.  
HSCs and hepatocytes were isolated by a multi-step ethylene glycol tetra-acetic acid 
(EGTA)/collagenase perfusion technique, through adequate microcannulation of small blood vessels to 
ensure efficient perfusion of tissue sample, as previously described (88).  
-perfusion solution 1, based on Hanks solution (Life Technologies, Carlsbad, CA) and EGTA 0,5 mM 
(Sigma-Aldrich, St Louis, MO); 
-perfusion solution 2, made of Hanks solution with collagenase type IV Sigma-Aldrich, St Louis, MO) 
0,25 mg/ml, CaCl2 2 mM, HEPES 20 mM (Sigma-Aldrich, St Louis, MO). 
All perfusion solutions were incubated at 37°C before use. Furthermore, we performed an ‘in vitro’ 
digestion in a Dnase type I (Roche, Basel Switzerland) solution, composed of Dnase type I 0,2 mg/ml, 
CaCl2 2mM and 1% Pen/Strep. 
Then, we separated HSCs, taking advantage of HSCs low density, due to a large amount of lipid 
droplets, since these cells store retinol as retinyl palmitate. For this purpose, we used a discontinuous 
density gradient of 15% and 11,5% Optiprep (Sigma-Aldrich, St Louis, MO), prepared according to the 
manufacturer's instruction.  
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Cells were cultured on plastic in DMEM medium supplemented with 10% FBS, 2 mM L-
glutamine, 100 units/ml penicillin and 0.1 mg/ml streptomycin; 100 nM insulin and 100 nM 
dexamethasone were added for hepatocytes. Isolated cells’ vitality was evaluated using flow cytometry 
and was around 99.5%. At least, three independent lots of freshly isolated cells were used for 
experiments. 
 
3.6 Isolation of leukocytes from peripheral blood 
 
Peripheral blood lymphocytes and monocytes were isolated from 16 healthy control subjects 
with normal coagulation and iron metabolism parameters and without cardiovascular disease. They 
were healthy volunteers, whose age was comprised between 20 and 40 years, with serum ferritin (50–
150 ng/ml) and transferrin saturation (25–45%) within the normal range, and without a previous history 
of cardiovascular disease. Written informed consent was obtained by each subject included in the 
study, which was approved by the Institutional Review Board of the Fondazione IRCCS Ca’ Granda.  
Mononuclear cells (monocytes and lymphocytes) were separated using the Lymphoprep 
gradient, because of their lower density (below 1.077 g/ml) compared to the erythrocytes and the 
polymorphonuclear (PMN) leukocytes (granulocytes). Therefore, these cells can be isolated starting 
from 200 ml of peripheral blood anticoagulated with citrate 3.2% (89) by centrifugation on an 
isoosmotic medium with a density of 1.077 g/ml, which allows the erythrocytes and the PMNs to 
sediment through the medium while retaining the mononuclear cells at the sample/medium interface.  
Monocytes and lymphocytes isolated were cultured in RPMI 1640 medium supplemented with 
10% FBS, 1% β-Mercaptoethanol and 1% Glutamine. After 24 hours, lymphocytes in media and 
monocytes attached were separated. In other experimental settings, M1 or M2 polarization of 
macrophages is inducted, treating monocytes with GM-CSF or MCSF (25 ng/ml) for 6 days. 
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3.7 In vitro treatments 
 
When specified, primary hepatocytes isolated from wild-type mice were pretreated for 1 hour 
with 50 μM PI3K inhibitor (LY294002 - Cell Signaling Technologies, Boston, United States) or in 
other experimental settings with 50 nM mTOR inhibitor (Rapamycin - Cell Signaling Technologies, 
Boston, United States), and then exposed to 0.33 μM insulin (Insuman Rapid, Sanofi Aventis) for 6 
hours. 
 
3.8 Patients 
We evaluated hepatic and adipose tissue samples of 119 unselected severely obese individuals 
(Bariatric surgery cohort), who underwent percutaneous liver biopsy performed during bariatric surgery 
for staging of liver damage severity. They included 23 obese patients without clinical and biochemical 
evidence of liver and metabolic disease and no history of alcohol abuse (men, >30 g/d; women, >20 
g/d) (referred to as normal liver group), 55 obese patients with steatosis (simple steatosis group) and 41 
obese subjects whose liver biopsies fulfilled the histological criteria for NASH (NASH group). NASH 
was considered to be present when a) steatosis, b) lobular inﬂammation and c) hepatocellular 
ballooning were concomitantly present. The inclusion criteria were liver biopsy for severe obesity, 
availability of RNA samples and clinical data. Individuals with increased alcohol intake, viral and 
autoimmune hepatitis, hereditary haemochromatosis and alpha1-antitrypsin deﬁciency or other causes 
of liver disease were excluded. Informed written consent was obtained from each patient and the study 
protocol was approved by the Ethical Committee of the Fondazione IRCCS Ca’ Granda, Milan and 
conforms to the ethical guidelines of the 1975 Declaration of Helsinki. The clinical characteristics of 
these patients are listed in Table 1.  
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Table 1. Clinical characteristics of 119 severely obese patients (Bariatric surgery cohort), of whom 
MBOAT7 hepatic and adipose tissue expression was evaluated.  
 
  
Normal liver 
 
(n=23) 
Simple 
steatosis 
(n=55) 
NASH 
 
(n=41) 
P value 
Age, years 44±2 42±2 46±1.5 0.30 
Gender, F (%) 22 (96) 37 (90) 42 (76) 0.04 
BMI, Kg/m2 38±10 41±5 44±8 0.0007 
IFG/T2DM, yes (%) 4 (17) 6 (15) 13 (24) 0.52 
Total cholesterol, mg/dL 195±56 219±38 207±49 0.23 
LDL cholesterol, mg/dL 136±34 136±29 126±40 0.36 
HDL cholesterol, mg/dL 62±11 58±13 48±16 0.0012 
Triglycerides, mg/dL 119±42 139±76 159±81 0.18 
ALT, IU/l 14 [11-21] 20 [14-24] 28 [20-44] 0.0001 
AST, IU/l 15 [12-18] 18 [16-20] 22 [18-27] 0.0005 
PNPLA3, I148M alleles yes (%) 12 (53) 21 (51) 37 (67) 0.2 
MBOAT7, T alleles yes (%) 12 (53) 30 (73) 40 (73) 0.2 
 
Values are mean ± standard deviation (SD), median [interquartile range], or number (%). BMI: body 
mass index; IFG: impaired fasting glucose (defined as fasting glucose >110 mg/dL); T2DM: type 2 
diabetes mellitus. 
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We evaluated also serum free fatty acids (FFAs) in 72 lean NAFLD patients (Hepatology 
service cohort), stratified by the presence of MBOAT7 T allele of risk, of whom serum samples were 
available. Clinical characteristics of NAFLD patients are listed in Table 2. 
Table 2. Clinical characteristics of 72 NAFLD patients (Hepatology service cohort), of whom serum 
FFAs concentration was evaluated. 
  
Hepatology 
service cohort (n=72) 
Age, years 47±11 
Gender, F (%) 8 (11) 
BMI, Kg/m2 26±3 
IFG/T2DM, yes (%) 7 (9.7) 
Total cholesterol, mg/dL 205±39 
LDL cholesterol, mg/dL 127±37 
HDL cholesterol, mg/dL 45±11 
Triglycerides, mg/dL 147±78 
ALT, IU/l 50 [18-75] 
AST, IU/l 28 [15-38] 
PNPLA3, I148M alleles yes (%) 52 (72) 
MBOAT7, T alleles yes (%) 46 (64) 
 
Values are mean ± standard deviation (SD), median [interquartile range], or number (%). BMI: body 
mass index; IFG: impaired fasting glucose (defined as fasting glucose >110 mg/dL); T2DM: type 2 
diabetes mellitus. 
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 All patients were previously genotyped for rs738409 (PNPLA3 I148M) and rs641738 
(MBOAT7/TMC4) using TaqMan 5’-nuclease assays (Life Technologies, Carlsbad, CA), as previously 
described (51) 
 
3.9 Gene expression analysis 
 
RNA was extracted from tissues or cell cultures using Trizol reagent (Life Technologies-
Thermofisher Scientific, Carlsbad, U.S.A). 1µg of total RNA was retro-transcribed with VILO random 
hexamers synthesis system (Life Technologies-Thermofisher Scientific, Carlsbad, U.S.A). Quantitative 
real time PCR (qRT-PCR) was performed by a ABI 7500 fast thermocycler (Life Technologies), using 
the Taqman Universal PCR Master Mix (Life Technologies, Carlsbad, CA) and Taqman probes for 
human MBOAT7 and the SYBR Green chemistry (Fast SYBR Green Master Mix; Life Technologies) 
for all other genes. All reactions were delivered in triplicate. Data were normalized to the β-actin gene 
expression and results were expressed as arbitrary units or fold increase as indicated in bar graphs. 
Primers are listed in Table 3.  
 
Table 3: Quantitative PCR analysis primer sequences 
 
 
Sense Antisense 
ApoB100 AAGCACCTCCGAAAGTACGTG CTCCAGCTCTACCTTACAGTTGA 
Fabp1 TCATGAAGGCAATAGGTCTGC TTGACGACTGCCTTGACTTT 
Fatp1 CGCTTTCTGCGTATCGTCTG GATGCACGGGATCGTGTCT 
FATP1 Hs CCACTTGGATGTCACCACTG GTGGGACCCTCCAGTAGACA 
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Fasn AAGGCTGGGCTCTATGGATT TGAGGCTGGGTTGATACCTC 
FASn Hs GCTGGGTGGAGTCTCTGAAG TGCAACACCTTCTGCAGTTC 
Cpt1 CCAGGCTACAGTGGGACATT GAACTTGCCCATGTCCTTGT 
Cxcl10 AGTGGGACTCAAGGGATCC GTCAGGCCAACAGAGCTGAT 
Mboat5 GGCCTCTCAATTGCTTATTTCA AGCACGACACATAGCAAGGA 
Mboat7 AAGAAAGCTGGACCTGGGC CTTCAGTGTCAACAGCAGCT 
Mttp GCTTCCGTTAAAGGTCACACA CAGCTGTTATCGTGACTTGGA 
Ppar-α ATGCCAGTACTGCCGTTTTC GGCCTTGACCTTGTTCATGT 
Srebp-1c GATCAAAGAGGAGCCAGTGC TAGATGGTGGCTGCTGAGTG 
SREBP1 Hs TGCATTTTCTGACACGCTTC CCAAGCTGTACAGGCTCTCC 
Tmc4 TTGACACTACAGGAGACGCC TTCTGCCTCCATGTTTCCCC 
Tnf-α CCCCAAAGGGATGAGAAGTT GTGGGTGAGGAGCACGTAGT 
β-actin GCTACAGCTTCACCACCACA AAGGAAGGCTGGAAAAGAGC 
 
  
3.10 Western blot analysis 
 
Total protein lysates were extracted from 20 mg of tissue or from cell cultures, using RIPA 
buffer containing 1 mmol/L Na-orthovanadate, 200 mmol/L phenylmethyl sulfonyl fluoride and 0.02 
μg/μL aprotinin. Equal amounts of proteins (50 μg) were separated by SDS-PAGE, transferred 
electrophoretically to nitrocellulose membrane (BioRad, Hercules, CA) and incubated with specific 
antibodies. Antibodies and concentration used are listed in Table 4. FoxA2 protein expression was 
assessed by western blot also in cytosolic and nuclear protein fraction in mice fasted 16 hours and then 
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refed for 15 minutes, 1 hour, 4 hours and 8 hours, in order to study the localization of this transcription 
factor in consequence to the rise of insulin signaling.  The separation and preparation of cytoplasmic 
and nuclear extract from tissue and cell lines was performed using NE-PER Nuclear and Cytoplasmic 
extraction reagents (Thermo Scientific, Carlsbad, U.S.A). 
 
Table 4. Antibodies and dilution used in Western blotting and immunohistochemistry. 
 
Antibody Catalog Number 
Thr308 Akt (1:1000) Cell signaling #2965 
Akt (1:1000) Cell signaling #2938 
FoxO1 (1:1000) Cell signaling #2880 
Foxa2 (1:1000) Abcam ab23630 
Histone H3 (1: 2000) Abcam ab1791 
Mboat7 (1:500) Sigma-Aldrich #AV49811 
P(T389)P70S6 Kinase (1:1000) Cell signaling #9205 
P70S6 Kinase (1:1000) Cell signaling #9202 
β-actin (1:1000) Santa-Cruz sc-1615 
  
 
3.11 Statistical Analysis 
 
Results are shown as means ± SD. Statistical analysis was performed using JMP 12.0 (SAS, 
Cary, NC) by using two-way analysis of variance (ANOVA) or chi-square test, where appropriate. 
Independent determinants of MBOAT7 down-regulation in liver and adipose tissue of severely obese 
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patients were assessed by multivariate generalized linear model analysis, adjusted for the confounders 
specified in the Results section. Determinants of FFAs increase in serum samples from lean NAFLD 
patients were identified by multivariate generalized linear model analysis. Correlations with FATP1 
increased expression in liver of severely obese patients were assessed by bivariate analysis. P values 
<0.05 (two-tailed) were considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
4. Results 
 
 
4.1 MBOAT7 down-regulation is associated with NAFLD severity 
independently of rs641737 C>T genotype 
 
To investigate whether the blunted expression of MBOAT7 may affect the liver damage 
severity independently of the presence of MBOAT7 T allele, we evaluated the hepatic MBOAT7 
expression in 119 Italian severely obese patients at risk of NASH, who underwent to liver biopsy 
during bariatric surgery (Bariatric surgery cohort). Demographic and clinical features are shown in 
Table 1. The main finding was that hepatic MBOAT7 mRNA levels progressively decreased from 
normal liver to simple steatosis and NASH (p<0.05 vs. normal liver; Fig. 6A).  
In particular, at multivariate generalized linear model, impaired fasting glucose/type 2 diabetes 
mellitus (IFG/T2DM; estimate -0.16±0.08; p=0.04), necroinflammation (estimate -0.31±0.11; p=0.005) 
and MBOAT7 risk allele (estimate -0.25±0.08; p=0.001) were independently associated with reduced 
MBOAT7 expression (Table 5; Fig. 6B-C), independently of several confounders. These data suggest 
that the down-regulation of hepatic MBOAT7 is associated with development and severity of NAFLD 
independently of MBOAT7 genotype.  
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Table 5: Variables associated with hepatic MBOAT7 gene expression at multivariate generalized 
linear model analysis, adjusted for all the clinical features reported in the table, in 119 severely obese 
patients who underwent to liver biopsy during bariatric surgery. 
 
 Estimate SE P value 
Age, years -0.00±0.01 0.98 
Sex, F -0.07±0.09 0.43 
BMI, Kg/m
2
 +0.00±0.01 0.87 
IFG/T2DM, yes -0.16±0.08 0.04 
Steatosis -0.02±0.07 0.84 
Necroinflammation -0.31±0.11 0.005 
PNPLA3, I148M alleles  -0.04±0.09 0.66 
MBOAT7, T alleles -0.25±0.08 0.004 
 
BMI: body mass index; IFG: impaired fasting glucose (defined as fasting glucose >110 mg/dL); 
T2DM: type 2 diabetes mellitus. 
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Fig. 6: Hepatic MBOAT7 expression decreases with liver damage severity. Hepatic MBOAT7 mRNA levels 
were evaluated by qRT-PCR in 119 severely obese patients stratified for liver damage severity (Normal liver; 
Control group (Cnt) n=23; Simple Steatosis n=55; NASH n=41) (A) for necroinflammatory grade (B) or for 
impaired fasting glucose/type 2 diabetes mellitus (IFG/T2DM) presence (C). Demographic, anthropometric and 
clinical characteristics of these patients are shown in Table S1. Data were normalized to β-actin and expressed as 
fold increase (Arbitrary Units - AU), compared to Cnt group. *p<0.05, **p<0.01 compared to Cnt.  
 
Furthermore, since the complex interplay between liver and adipose tissue in insulin resistance 
(IR) conditions is involved in the development and in the progression of NAFLD, we assessed also the 
adipose tissue expression of MBOAT7 in this cohort of obese patients. Notably, the expression of 
MBOAT7 in the adipose tissue was 9-fold lesser than in the liver. At multivariate generalized linear 
model analysis, IFG/T2DM (estimate -0.28±0.12; p=0.01) and MBOAT7 risk allele (estimate -
0.31±0.13; p=0.02) were independently associated with MBOAT7 expression after adjustment for age, 
sex, BMI, presence of T2DM, the severity of liver disease, PNPLA3, I148M alleles and MBOAT7, T 
A B 
C 
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alleles, confirming the effect of IFG/T2DM and of the rs641738 variant on the down-regulation of 
MBOAT7 mRNA levels also in adipose tissue (Table 6).  
 
Table 6: Variables associated with adipose MBOAT7 gene expression at multivariate generalized 
linear model analysis in 119 severely obese patients who underwent to adipose tissue biopsy during 
bariatric surgery. 
 
 Estimate SE P value 
Age, years 0.014±0.01 0.15 
Sex, F -0.21±0.12 0.09 
BMI, Kg/m
2
 0.00±0.02 0.77 
IFG/T2DM, yes -0.28±0.12 0.01 
Steatosis 0.03±0.12 0.78 
Necroinflammation 0.07±0.17 0.66 
PNPLA3, I148M alleles -0.28±0.16 0.09 
MBOAT7, T alleles -0.31±0.13 0.02 
 
BMI: body mass index; IFG: impaired fasting glucose (defined as fasting glucose >110 mg/dL); 
T2DM: type 2 diabetes mellitus. 
 
Then, to dissect the impact of the rs641738 C>T variant on specific hepatic cell types, we 
isolated hepatocytes and human hepatic stellate cells (hHSCs) from non-neoplastic tissue obtained from 
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explanted or resected livers of 17 patients. MBOAT7 mRNA levels were similar between hepatocytes 
and hHSCs. However, the rs641738 variant was associated with reduced MBOAT7 expression only in 
hepatocytes (p<0.05 vs. CC; Fig. 7), indicating that the effect of MBOAT7 down-regulation on TG 
accumulation, previously described, may be a cell-autonomous property of hepatocytes. 
 
 
 
Fig. 7: MBOAT7 rs641738 C>T variant affects MBOAT7 expression in hepatocytes, but not in human hepatic 
stellate cells (hHSCs). MBOAT7 mRNA levels were evaluated by qRT-PCR in freshly human hepatocytes and 
activated hHSCs (at third passage of culture) isolated from patients wild-type (CC) or carriers of MBOAT7 T 
allele. mRNA levels were normalized for β-actin and expressed as fold increase (Arbitrary Units - AU), as 
compared to CC genotype. (n=17 hepatocytes; n=12 hHSCs) *p<0.05 compared to protective CC genotype. 
 
Finally, to gain insight into impact of MBOAT7 genotype in inflammatory cells, we isolated 
peripheral blood lymphocytes and monocytes from 16 healthy subjects. MBOAT7 gene expression 
tended to decrease both in lymphocytes and monocytes of patients carrying T allele of risk (p<0.05 vs. 
CC and p=0.09 vs. CC respectively; Fig. 8). MBOAT7 was highly expressed by human primary 
monocytes (7-fold more than in hepatocytes and HSCs). Interestingly, differentiation of monocytes 
with polarization to both M1 or M2 macrophages induced MBOAT7 reduction, independently of the 
presence of T allele (p<0.05 vs. monocytes; Fig. 8). These data are consistent with the hypothesis that 
MBOAT7 down-regulation may be involved in priming macrophages for triggering inflammation. 
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Fig. 8: MBOAT7 expression decreases with inflammatory cells activation. MBOAT7 mRNA levels were 
evaluated by qRT-PCR in freshly isolated human lymphocytes, monocytes and M1 or M2 macrophages, 
stratified for genotype. mRNA levels were normalized to β-actin and expressed as fold increase (Arbitrary Units 
- AU), compared to CC lymphocytes. (n=7 lymphocytes; n=15 monocytes; n=3 M1 and M2) *p<0.05 compared 
to protective CC genotype. 
 
4.2 Mboat7 expression is dampened in Lep
ob/ob 
mice  
 
To dissect the contribution of different pathophysiological triggers in Mboat7 regulation, we 
next evaluated the hepatic Mboat7 expression in experimental mice models of NAFLD, such as 
methionine choline deficient diet (MCD), that induces NASH, but not IR, and in genetically obese 
Lep
ob/ob 
mice which develop IR. As expected, hepatic TG content was higher in MCD-fed mice 
compared to mice fed standard diet (SD) (p<0.05; Fig. 9A-B), but more so in Lep
ob/ob 
mice (p<0.01 vs. 
SD-fed mice). Fasting insulin was increased in Lep
ob/ob 
mice compared to wild-type mice fed SD or 
MCD (p<0.01; Fig. 9C) and expectedly they showed higher glucose levels during fasting and 
following insulin tolerance test (p<0.05, p<0.01 respectively; Fig 9D, E), confirming the insulin 
resistance in Lep
ob/ob 
mice. In line with the results obtained in patients, hepatic Mboat7 mRNA and 
protein expression were reduced in MCD-fed mice (p<0.05 vs. SD-fed mice; Fig. 9F-G), but more so 
in Lep
ob/ob 
mice (p<0.01 vs. SD-fed mice; Fig. 9F-G), in which NAFLD and IR coexist. These data 
43 
 
suggest that more severe hepatic Mboat7 down-regulation in Lep
ob/ob 
mice as compared to wild-type 
mice fed MCD may be explained by the presence of IR. 
 
 
              
                          
                        
Fig. 9: Mboat7 expression decreases in experimental model of NASH. Hematoxylin and Eosin (H&E) stain of 
hepatic specimens (A) and hepatic triglyceride (TG) content (B) from wild-type mice fed standard diet (referred 
to as Cnt) or Methionine choline deficient diet (MCD) and from Lep
ob/ob 
mice. Original magnification: 200X. 
A 
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Serum insulin was measured in Cnt or MCD-fed wild-type mice and in Lep
ob/ob 
mice, fasted for 16 hours (n=10 
per group) (C). Insulin tolerant test (ITT, 0.75 U/Kg i.p). was performed in Lep
ob/ob 
mice fasted for 16 hours.  
The circles refer to Cnt; squares refer to wild-type mice fed MCD and triangles to Lep
ob/ob
 mice. 10 mice per 
group were analyzed. Data are expressed as means ± SD. *p<0.05, **p<0.01 compared to Cnt mice at basal 
condition, before insulin administration (T0) (D). Area under the curve (AUC) after ITT in Cnt, MCD and 
Lep
ob/ob
 mice (**p<0.01) (E). Hepatic Mboat7 mRNA levels were evaluated by qRT-PCR. mRNA levels were 
normalized for -actin and expressed as fold increase (Arbitrary Units - AU), as compared to Cnt (F). Western 
blot and quantification of Mboat7 protein levels in livers from Cnt, MCD and Lep
ob/ob 
mice, fasted for 16 hours 
(n=10 per group) (G). *p<0.05, **p<0.01 compared to Cnt. 
 
4.3 InsR+/- mice show blunted Mboat7 expression, independently of diet 
 
To evaluate the independent contribution of hepatic fat accumulation, IR, and inflammation, we 
managed to dissociate these components, that are usually intertwined in patients, in an experimental 
model of NASH. To this end, we studied Mboat7 regulation in Insulin receptor haplo-insufficient mice 
(InsR+/-), characterized by development of hyperinsulinemia, fed standard or MCD diet for 6 weeks. 
InsR+/- mice developed more severe steatosis compared to wild-type MCD-fed mice (Fig. 10A) (36). 
Mboat7 mRNA levels were reduced in InsR+/- compared to wild-type mice, independently of the diet 
(p<0.05; Fig. 10B). However, Mboat7 protein levels in InsR+/- mice fed-SD only slightly decreased 
compared to wild-type mice fed-SD (p=0.1; Fig. 10C). These data suggest that altered insulin signaling 
may play a causal role in determining Mboat7 down-regulation. The presence of inflammation, induced 
by MCD, did not further reduce Mboat7 expression in InsR+/- mice compared to wild-type littermates 
feeding the same diet, probably because of the impaired activation of hepatic leukocytes and the lower 
release of pro-inflammatory cytokines, identified in InsR+/- mice (data not shown). 
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Fig. 10: Insulin receptor haplo-insufficient (InsR+/-) mice show decreased Mboat7 expression, independently of 
diet. H&E stain of hepatic specimens from wild-type and InsR+/- mice fed standard diet (SD) or MCD (A). 
Original magnification: 200X. Hepatic Mboat7 mRNA levels were evaluated by qRT-PCR. mRNA levels were 
normalized for β-actin and expressed as fold increase (Arbitrary Units - AU), as compared to wild-type SD 
(InsR+/+ SD) (B). Western blot and quantification of Mboat7 protein levels in livers from wild-type and InsR+/- 
MCD mice, fasted for 16 hours (n=10 per group) (C). *p<0.05, **p<0.01 compared to InsR+/+ SD. 
 
Then, to test whether down-regulation of Mboat7 in response to IR may be generalizable to 
other models of NAFLD, we evaluated its expression also in InsR+/- or wild-type mice fed MCD 
supplemented with fructose, a major substrate for hepatic lipogenesis. Additional fructose 
supplementation was associated with more severe steatosis (data not shown), but did not further 
A B 
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decrease hepatic Mboat7 mRNA levels in InsR+/- mice fed MCD compared to InsR+/- mice fed SD 
(Fig. 11). These data suggest that IR, but not hepatic lipid accumulation alone, specifically induces 
Mboat7 down-regulation. 
 
 
Fig. 11: Fructose supplementation to MCD does not exacerbate Mboat7 down-regulation in InsR+/- mice. 
Hepatic Mboat7 mRNA levels were evaluated by qRT-PCR in InsR+/- and wild-type mice fed MCD 
supplemented with 30% fructose. mRNA levels were normalized to β-actin and expressed as fold increase 
(Arbitrary Units - AU), compared to wild-type SD-fed mice (InsR+/+ SD). 
 
4.4 Hepatic Mboat7 expression depends on nutritional state 
 
To examine whether Mboat7 is physiologically regulated by excursions in insulin levels 
following fasting-refeeding cycles, we analyzed its expression in male mice after overnight fasting and 
then after a time course of refeeding (15 minutes, 1 hour, 4 hours, 8 hours). Biochemical features of 
wild-type male mice fasted for 16 hours or refed are shown in Table 7.  
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Table 7. Biochemical features of wild-type male mice fasted for 16 hours or refed (15 min, 1 hour, 4 
hours or 8 hours). 
 
 T0 T15’ T1h T4h T8h P 
value 
Liver/Body Weight  0.04±0.002 0.05±0.002 0.05±0.002 0.053±0.003 0.06±0.002 0.02 
Glucose (mg/dL) 101±17.1 108±14.6 154±18.4 116±19.4 104±15 0.04 
Serum Triglycerides 
(mg/dL) 
75±12.7 63±19.5 56±8.5 134±63 106±39 0.0003 
Hepatic Triglycerides 
(%) 
7.4±2 4.6±2.1 4±2.3 3.6±2.9 2.6±1.6 0.02 
Cholesterol (mg/dL) 
99.7 ±23.1 90.2 ±7.5 81.4±24.2 102.6±15.1 101.7±15.3 0.2 
ALT (mg/dL) 44 [40-50] 52 [48-60] 60 [48-64] 72 [62-102] 40 [36-72] 0.4 
 
Values are expressed as mean ± standard deviation (SD) or median [interquartile range]. N=7 
mice/group. 
 
 
Concomitantly with the rise of insulin levels (p<0.05 vs. fasting (T0); Fig. 12A) and the 
activation of hepatic insulin signaling, supported by an increased phospho-Akt/Akt ratio, the main 
intracellular mediator of insulin signaling activation, (p<0.05 vs. T0; Fig. 12A) and by a decreased 
Forkhead box protein O1 (FoxO1), the key transcription factor of gluconeogenesis, (p<0.05 vs. T0; Fig. 
12A), both hepatic mRNA and protein levels of Mboat7 were down-regulated by refeeding (p<0.05 vs. 
T0; Fig. 12B). Consistently with these results, Mboat7 mRNA levels were also down-regulated in 
proximal intestine and in adipose tissue after refeeding (p<0.05 vs. T0; Fig. 12C-D), confirming the 
ability of insulin signaling activation to induce Mboat7 down-regulation also in other tissues.  
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Fig. 12: Hepatic Mboat7 expression depends on nutritional state. Western blot and quantification of hepatic 
pThr308-Akt/Akt ratio, FoxO1 (A) and Mboat7 (B) protein levels and serum insulin evaluated in wild-type 
mice, fasted for 16 hours (T0) or refed for 15 minutes (T15’), 1 hour (T1h), 4 hours (T4h) or 8 hours (T8h) (n=7 
per group). Hepatic (B), intestinal (C) and adipose tissue (D) Mboat7 mRNA levels were evaluated by qRT-
PCR. mRNA levels were normalized for β-actin and expressed as fold increase (Arbitrary Units - AU), as 
compared to T0. *p<0.05, **p<0.01 compared to T0.  
 
Since MBOAT5, another member of MBOAT family, have a similar ability to MBOAT7 to 
catalyze the incorporation of free arachidonic acids preferentially into the phosphatidylcholine (PC) in 
B 
C 
A 
D 
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order to promote unsaturation of membrane lipids and lipoproteins production, and loss-of-function 
mutation in Mboat5 have been recently associated with an increased risk of hepatic steatosis onset, we 
sought to evaluate whether Mboat5 expression could also be influenced by insulin peak, due to the 
refeeding state. We found that Mboat5 mRNA levels were decreased after refeeding in liver and 
proximal intestine, where it is most abundant (p<0.05 vs. T0; Fig. 13A-B). However, during fasting 
hyperinsulinemia associated with NAFLD development Mboat7 and Mboat5 showed a discordant 
regulation. Indeed, Lep
ob/ob 
and InsR+/- MCD-fed mice displayed enhanced hepatic expression of 
Mboat5 (p<0.05 vs. SD-fed mice; Fig. 12C-D).  
 
       
   
Fig. 13: Mboat5 increases in insulin resistant mice. Hepatic (A) and intestinal (B) Mboat5 mRNA levels were 
evaluated by qRT-PCR, normalized to -actin and expressed as fold increase (Arbitrary Units - AU), compared 
to fasting condition (T0). *p<0.05 compared to T0. Hepatic Mboat5 mRNA levels were evaluated also in wild-
type and InsR+/- mice fed standard diet (Cnt) or MCD and in Lep
ob/ob 
mice (C, D). All data are expressed as fold 
increase (Arbitrary Units - AU), compared to Cnt.  
A B 
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4.5 Mboat7 down-regulation is dependent on insulin signaling activation 
in primary hepatocytes 
 
To test whether Mboat7 down-regulation may be insulin-dependent, we isolated primary 
hepatocytes from wild-type male mice and we treated them with insulin (0.33 μM) alone or in 
combination with a selective inhibitor of insulin signaling activation (LY294002) which specifically 
acts on PI3Kinase, the kinase upstream to Akt. In keeping with the data obtained from the in vivo 
models, insulin addition to the culture media forced around 50% of Mboat7 protein levels reduction 
(p<0.01 vs. untreated hepatocytes; Fig. 14). Moreover, the effect of insulin on Mboat7 dampening was 
completely abolished by the pharmacological inhibition of the signaling pathway by the PI3Kinase 
inhibitor (p<0.01 vs. insulin-treated hepatocytes; Fig. 14).  
 
Fig. 14: Mboat7 down-regulation is dependent on insulin signaling activation in primary hepatocytes. Western 
blot and quantification of pThr308-Akt/Akt ratio and Mboat7 protein levels in hepatocytes isolated from wild-
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type mice and treated with insulin (0.33 μM), LY294002 (50 μM) or a combination of both for 6 hours; *p<0.05, 
**p<0.01 compared to wild-type untreated cells.  
 
Conversely, mammalian target of Rapamycin (mTOR) pharmacological inhibition did not 
restore Mboat7 expression (Fig. 15).  
 
 
Fig. 15: mTORC1 inhibition does not affect the insulin-dependent MBOAT7 down-regulation. Western blot and 
quantification of pThr389-P70S6 kinase and Mboat7 protein levels in hepatocytes isolated from wild-type mice 
and treated with insulin (0.33 μM), Rapamycin (50 nM) or a combination of both for 6 hours; *p<0.05, **p<0.01 
compared to wild-type untreated cells.  
 
These data suggest that insulin down-regulates Mboat7 protein expression in hepatocytes in a 
PI3Kinase-depedent manner. Consistently, in hepatocytes haplo-insufficient for the insulin receptor 
(InsR+/-) insulin-mediated suppression of Mboat7 was lost (p<0.01 vs. untreated hepatocytes; Fig. 16). 
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Fig. 16: In InsR+/- hepatocytes, the insulin-mediated suppression of Mboat7 expression is lost. Mboat7 
expression in hepatocytes isolated from wild type and InsR+/- mice and treated with insulin (0.33 μM) for 6 
hours was evaluated by qRT-PCR, normalized for β-actin and expressed as fold increase (Arbitrary Units - AU), 
compared to wild-type untreated hepatocytes. *p<0.05, **p<0.01. 
 
4.6 Mboat7 down-regulation by insulin in primary mouse hepatocytes 
requires FoxO1  
 
 To investigate the mechanism of regulation of MBOAT7 expression by insulin signaling, we 
next focused on clarifying the specific transcription factors, involved in the insulin-dependent 
mechanisms of MBOAT7 regulation. On this purpose, we analyzed the sequence of MBOAT7 
promoter, using the bioinformatics software Genomatix. This software predicted the presence of the 
Forkhead family transcription factor binding sites, among which Forkhead Box O1 (FoxO1) and 
Forkhead Box A2 (FoxA2) in MBOAT7 promoter, exactly localized close to the transcription start site 
of the MBOAT7 main isoform (isoform 1, 55 kDa). A scheme of MBOAT7 promoter is illustrated in 
Fig. 17. The presence of a binding site for FoxA2 on MBOAT7 promoter was previously confirmed by 
a chip-seq peak in hepatocytes, at the same position predicted by Genomatix (founded in the database 
Harmonizone, http://amp.pharm.mssm.edu/Harmonizome/). FoxO1 and FoxA2 are key mediators of 
insulin signaling at transcriptional level, regulating gluconeogenesis. Insulin signaling through Akt 
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activation is a negative regulator of these two transcription factors, directly determining their 
phosphorylation and exclusion from the nucleus to cytoplasm and their consequent degradation. Thus, 
FoxO1 and FoxA2 may represent good candidates to mediate the insulin-dependent effect on 
MBOAT7 down-regulation.  
 
 
Fig. 17: FoxO1 and FoxA2 are predicted to bind to MBOAT7 promoter. The Fkhd family transcription factor 
binding sites and the localization of their consensus sequences on MBOAT7 promoter (isoform 1) were 
predicted by the bioinformatics software Genomatix. The presence of a binding site for FoxA2 in hepatocytes on 
MBOAT7 promoter was confirm by the chip-seq peak, revealed by Harmonizome. *p<0.05 for matrix family 
enrichment. 
 
For this reason, we further characterize the effect of FoxO1 and/or FoxA2 deletion by 
exploiting morpholino antisense oligonucleotides (MPO) for silencing these transcription factors in 
wild-type primary mouse hepatocytes. FoxO1-MPO hepatocytes showed 50% reduced FoxO1 protein 
expression (p<0.05 vs. untreated hepatocytes). Similar to what occurred in InsR+/- hepatocytes, the 
insulin-dependent Mboat7 down-regulation was abrogated in FoxO1-MPO hepatocytes (p<0.05 vs. 
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FoxO1-MPO hepatocytes in absence of insulin stimulation), suggesting that FoxO1 is required to 
mediate the Mboat7 regulation by insulin (Fig. 18). 
 
Fig. 18: Mboat7 down-regulation by insulin in primary mouse hepatocytes requires FoxO1. Hepatocytes 
isolated from wild type mice were treated with FoxO1-specific morpholino antisense oligonucleotides (MPO) or 
scramble (Scr) (10 μM) administered for 24 hours, in presence or not of insulin (0.33 μM); FoxO1 protein levels 
were normalized for β-actin.  Mboat7 protein levels were evaluated in wild-type hepatocytes treated with 
FoxO1-MPO or scramble, in presence or not of insulin (0.33 μM); *p<0.05, **p<0.01 compared to Scr.  
  
Remarkably, the hampered Mboat7 expression that we had observed in InsR+/- hepatocytes 
compared to wild-type was avoided by FoxO1-MPO treatment (p<0.05 vs. InsR+/- hepatocytes treated 
with scramble; Fig. 19A). The same result was obtained in mice fed MCD for 3 weeks, after i.v. 
weekly injection of FoxO1-MPO (p<0.05 vs. Scr-MPO mice fed MCD diet; Fig. 19B). 
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Fig. 19: InsR+/- treated with FoxO1-MPO re-stabilize Mboat7 mRNA levels comparable to that observed in 
wild-type. Mboat7 mRNA levels were evaluated in wild type (InsR+/+) and InsR+/- hepatocytes treated with 
FoxO1-MPO or scramble; *p<0.05, **p<0.01 compared to InsR+/+ Scr (A). InsR+/- mice were treated with 12.5 
mg/kg of FoxO1-MPO or scramble administered i.v. once weekly for 3 weeks during MCD feeding (n=5 mice 
per group); Mboat7 mRNA levels were normalized for β-actin; *p<0.05 compared to Scr (B). 
 
4.7 Hepatic Mboat7 silencing induces microvesicular steatosis in vivo  
 
Finally, to determine the impact of Mboat7 down-regulation on hepatic steatosis development, 
we silenced Mboat7 in wild-type male mice, by i.v. administration for 4 consecutive days of specific 
MPO. Biochemical features of wild-type mice treated with Scramble and MPO Mboat7 are shown in 
Table 8.  
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Table 8. Biochemical features of wild-type mice, treated with Scramble and MPO Mboat7. 
 
 
 Scramble MPO Mboat7 P value 
Liver/Body Weight  0.04±0.003 0.045±0.004 0.09 
Glucose (mg/dL) 94±26 84±32 0.3 
Insulin (ng/mL) 1.07±0.03 1.02±0.07 0.16 
Cholesterol (mg/dL) 104 ±23.5 129 ±24.3 0.09 
Triglycerides (mg/dL) 93±9.5 108±31 0.2 
FFAs (nmol/uL) 0.69±0.23 0.9±0.15 0.07 
ALT (mg/dL) 46 [44-52] 46 [42-49] 0.43 
 
Values are expressed as mean ± standard deviation (SD) or median [interquartile range]. N=6 mice per 
group. 
 
MPO induced a 45% silencing of hepatic Mboat7 (p<0.05 vs. Scr-MPO; Fig. 20A), which 
comparable to that associated with carriage of the genetic risk variant in humans. This resulted in a 
80% increase in hepatic triglyceride content (p<0.05 vs. Scr-MPO; Fig. 20B) and in microvesicular 
steatosis development, but without altering circulating glucose, insulin and lipid levels (Table 8). 
These data are consistent with the notion that Mboat7 down-regulation has a causal role in the 
pathogenesis of steatosis, consistently with genetic epidemiological data (60, 61).  
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Fig. 20: Hepatic Mboat7 silencing induces microvesicular steatosis in vivo. Wild-type mice were treated with 
12.5 mg/kg of Mboat7-MPO or scramble (Scr) administered i.v. daily for 4 days (n=6 per group) and were 
fasted for 16 hours before sacrifice. Western blot and quantification of hepatic Mboat7 protein levels were 
normalized for β-actin; *p<0.05 compared to Scr mice (A). H&E staining and intrahepatic TG content 
assessment in Mboat7-MPO or Scr mice (B). Original magnification: 400X. 
 
Steatosis development in mice silenced for Mboat7 was apparently not explained by induction 
of de novo lipogenesis. Conversely, hepatic Srepb1c and Fasn mRNA levels were markedly down-
regulated (p<0.01 vs. Scr-MPO; Fig. 21A), possibly in an attempt to compensate for increased steatosis 
by suppressing lipogenesis. On the other hand, expression of genes regulating β-oxidation (Pparα and 
Cpt1) and VLDL export (Mttp and ApoB100) were not affected by  Mboat7 silencing (Fig. 21B, C). 
However, mRNA expression of fatty acids transporters (Fatp1 and Fabp1) was significantly 
upregulated in Mboat7-MPO mice vs. controls (p<0.01 and p<0.05 vs. Scr-MPO respectively; Fig. 
21D).  
A 
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Next, in order to validate these findings in the clinic, we then evaluated the mRNA expression 
of FATP1 in 119 obese patients of bariatric surgery cohort. At bivariate analysis, we found a positive 
correlation between FATP1 gene expression and the presence of T2DM (estimate +0.76±0.28; 
p=0.007) and an inverse correlation with decreased MBOAT7 hepatic expression (estimate -0.32±0.15; 
p=0.03). These results support the hypothesis that the predisposition to hepatic fat accumulation 
associated with down-regulation of hepatic MBOAT7 may be related to an increase in the uptake of 
FFAs from circulation into hepatocytes. 
 
 
Fig. 21: Steatosis development in Mboat7-MPO mice is apparently explained by enhanced expression of fatty 
acids transporters. Hepatic Srebp1c and Fasn (genes involved in de novo lipogenesis) (A), Pparα and Cpt1 
(genes involved in β-oxidation) (B), Mttp and ApoB100 (lipid exporting marker) (C), Fatp1 and Fabp1 (fatty 
acids transporters) (D) expression was evaluated by qRT-PCR; mRNA levels were normalized to β-actin. Data 
are expressed as fold increase compared to Scr mice (n=6 mice per group; *p<0.05, **p<0.01). 
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On the other hand, Mboat7 silencing was not associated with alterations in the hepatic 
expression of inflammatory cytokines and chemokines (such as Tnf-α and Cxcl10) (Fig. 22A), 
suggesting that, at least in this acute model, it exerts its main effect on liver disease by predisposing to 
hepatic fat accumulation, and not on inflammation. Furthermore, there was no modification in the 
expression of genes related to Mboat7 (Tmc4 at the linked locus and the paralogue Mboat5; Fig. 22B) 
was identified, highlighting the impossibility of Mboat5 to compensate to Mboat7 reduction.  
 
 
Fig. 22: No alteration in inflammation or in genes related to Mboat7 is identified in Mboat7-MPO mice. Tnfα 
and Cxcl10 (inflammatory markers) (A) and Tmc4 and Mboat5 (B) expression was evaluated by qRT-PCR; 
mRNA levels were normalized to β-actin. Data are expressed as fold increase compared to Scr mice (n=6 mice 
per group; *p<0.05, **p<0.01). 
 
The microvesicular steatosis development and the enhanced expression of fatty acids 
transporters in Mboat7-silenced mice was associated with slightly increased circulating FFAs 
compared to Scr-MPO mice (Table 8), possibly due to Mboat7 silencing also in adipose tissue (p<0.05 
vs. Scr-MPO; Fig. 23A), leading to increased FFAs flux from adipose tissue to the liver. Notably, MPO 
did not affect Mboat7 protein levels in brain, probably because it did not pass the hemato-encephalic 
barrier (Fig. 23B).   
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Fig. 23: Mboat7 is silenced also in adipose tissue of Mboat7-MPO mice, but not in brain. Western blot and 
quantification of Mboat7 protein levels in adipose tissues (A) and brains (B) from Mboat7-MPO or Scr mice 
fasted for 16 hours and normalized for β-actin; *p<0.05 compare d to Scr mice. 
 
For this reason, we assessed also serum FFAs in 72 lean NAFLD patients (Hepatology service 
cohort), stratified by the presence of MBOAT7 T allele of risk, in order to minimize the confounding 
effect of obesity. Demographic and clinical features of subjects included are shown in Table 2. At 
multivariate analysis, applying a generalized linear model, T2DM (estimate +0.03±0.008; p=0.0006) 
and MBOAT7 risk allele (estimate +0.01±0.005; p=0.02) were independently associated with FFAs 
circulating concentration (Table 9) after adjustment for age, sex, BMI, presence of T2DM, PNPLA3, 
I148M alleles and MBOAT7, T alleles. These data are consistent with the hypothesis that in NAFLD 
patients the down-regulation of hepatic MBOAT7, caused by the presence of T allele may be involved 
in enhanced uptake of FFAs to the liver, promoting early stages of liver steatosis development. 
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Table 9: Variables associated with FFAs dosage (nmol/μL) at multivariate generalized linear model 
analysis in 72 NAFLD patients (Hepatology cohort). 
 
 Estimate SE P value 
Age, years 0.0005±0.0003 0.15 
Sex, F 0.007±0.006 0.25 
BMI, Kg/m
2
 -0.001±0.001 0.21 
T2DM, yes 0.03±0.008 0.0006 
PNPLA3, I148M alleles -0.006±0.006 0.29 
MBOAT7, T alleles 0.01±0.005 0.02 
 
BMI: body mass index; T2DM: type 2 diabetes mellitus. 
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5. Discussion  
 
In this study we examined whether MBOAT7 down-regulation may be involved in mediating 
the effect of IR in the pathogenesis of liver disease by favoring steatosis development. To this end, we 
first showed that hepatic MBOAT7 expression is associated with the severity of inflammation and T2D 
in patients at risk of NASH, independently of the risk genotype. Association of hepatic Mboat7 down-
regulation with hepatic steatosis was confirmed in experimental models, but importantly IR induced 
down-regulation of Mboat7 independently of steatosis. Furthermore, we went on to show that Mboat7 
is physiologically regulated by fasting-feeding cycles in the liver, depending on activation of insulin 
signaling in primary hepatocytes via a InsR/Akt/FoxO1 dependent pathway. Finally, acute down-
regulation of hepatic Mboat7 in vivo in mice determined the development of microvesicular steatosis 
by a mechanism encompassing up-regulation of fatty acids importers in hepatocytes, which was 
mirrored in patients carrying MBOAT7 T risk allele. 
In the first part of this study, we evaluated whether the blunted expression of MBOAT7 may be 
involved in the development and progression of NAFLD, independently of the presence of MBOAT7 
rs641738 C>T variant, which has been previously associated with steatosis onset and progressive 
NAFLD (60, 63). Moreover, we examined the clinical and genetic determinants of hepatic MBOAT7 
expression in severely obese patients at risk of NASH. We found that hepatic MBOAT7 expression 
progressively decreased with liver damage severity. In particular, impaired fasting glucose/type 2 
diabetes mellitus (IFG/T2DM), necroinflammation and the presence of the T risk allele were 
independently associated with reduced MBOAT7 expression. Nonetheless, in these patients IFG/T2DM 
and MBOAT7 risk allele were independently associated with MBOAT7 hampered expression also in 
adipose tissue. Given the complex interplay between liver and adipose tissue in IR development, that is 
the strongest predictor of progressive NAFLD, MBOAT7 down-regulation in these tissues in IR 
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conditions may further contribute to liver damage development and progression independently of 
MBOAT7 genotype. To note, the MBOAT7 variant has been recognized as a risk factor for liver 
damage severity also in different aetiologies (64, 65), suggesting that the MBOAT7 dumped expression 
may represent a common mechanism of liver injury.  
MBOAT7 is involved in the reacylation of phospholipids as part of the remodeling pathway 
‘Land’s cycle’ by specifically transferring polyunsaturated acyl-CoAs, such as arachidonoyl-CoA, to 
lysophosphatidylinositol and other lysophospholipids, thereby allowing to achieve an adequate level of 
desaturation of the membranes and to maintain a low amount of free arachidonic acid, that is a potent 
trigger for liver inflammation and fibrosis. Carriers of the rs641738 T risk allele had reduced 
expression and synthesis of the MBOAT7 protein in the liver and changes in plasma 
phosphatidylinositol species consistent with decreased MBOAT7 activity (60, 61). These observations 
suggest that reduced enzymatic activity of MBOAT7 may explain, on one side, the increased liver fat 
accumulation and the steatosis onset, and on the other side, liver damage worsening into NASH and 
advanced fibrosis. Indeed, higher levels of circulating bioactive proinflammatory metabolites of 
arachidonic acid have been reported in patients with NASH. Evaluation of MBOAT7 expression in 
primary cultures of specific human cell populations are consistent with this hypothesis. Specifically, 
the rs641738 T risk allele was associated with reduced MBOAT7 expression in hepatocytes, but not in 
hHSCs, thereby suggesting that hepatocellular MBOAT7 down-regulation may directly account for 
predisposition to TG accumulation by altering the biochemical properties of cell membranes. However, 
in lymphocytes and monocytes, characterized by high MBOAT7 expression, the T risk allele was also 
associated with down-regulation of gene expression,  which was also observed during cell activation. 
We could therefore hypothesize that MBOAT7 down-regulation may be involved in priming 
macrophages for triggering inflammation, thus determining the switch from simple steatosis to 
steatohepatitis. 
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In line with this hypothesis, in the second part of this study, we showed that MBOAT7 
expression was reduced in experimental models of NAFLD, such as MCD diet, but more so in 
genetically obese Lep
ob/ob 
mice which develop IR and in Insulin receptor haplo-insufficient mice (InsR 
+/-), characterized by hyperinsulinemia despite the lack of increased adiposity and of significant 
steatosis. A possible explanation could be due to the fact that despite the significantly reduced gene 
expression, Mboat7 protein levels only slightly decreased in InsR+/- mice fed standard diet compared 
to wild-type, preserving its total enzymatic activity more than in patients carriers T allele of risk or in 
acute silencing, where this reduction is more pronounced. Thus, we detected a strong link between 
Mboat7 down-regulation and hyperinsulinemia associated with IR, but not with steatosis alone.  
We hypothesized that insulin signaling may be responsible for down-regulation of MBOAT7 
expression during NAFLD, thereby linking IR to the development of fatty liver and steatohepatitis. To 
test this, we next examined the physiological regulation of hepatic Mboat7 during the transition from 
fasting to refeeding in vivo in mice. Indeed, we observed that hepatic Mboat7 expression decreased 
during refeeding in insulin responsive tissues (liver, adipose tissue and proximal intestine), 
concomitantly with the rise of insulin levels and the activation of hepatic insulin signaling through 
PI3K and AKT.  
Then, to gain insight into the physiological impact of Mboat7 regulation by insulin, we 
compared the expression pattern to that of Mboat5, the closest paralogue which has been shown to 
favor lipoproteins secretion and whose hepatic specific silencing has been demonstrate to induce 
steatosis (82, 83). We observed that Mboat5 was similarly down-regulated following refeeding in the 
liver. However, during hyperinsulinemia Mboat7 and Mboat5, showed a divergent regulation, with up-
regulation of Mboat5 expression. This may result in amelioration of saturated free fatty acid-induced 
ER stress, lowering also blood glucose and insulin levels in Lep
ob/ob 
mice (81, 84). Furthermore, 
Mboat5 is regulated by liver X receptors (LXR), that is generally active in experimental models of IR 
65 
 
(81, 84). Conversely, mice with specific deletion of hepatic Mboat5 display decreased arachidonic 
acid-containing phospholipids in the liver and an increased risk of hepatic steatosis onset, due to altered 
lipid kinetics within hepatocytes, and inflammation (82, 83).  
The next question we addressed is whether and how insulin regulates hepatic Mboat7 
expression. To test whether insulin has a direct causal role in the regulation of Mboat7 expression, we 
isolated primary mouse hepatocytes and demonstrated that exposure to insulin was able to down-
regulate Mboat7, suggesting this is a cell autonomous property of hepatocytes. In keeping with these 
results, we showed, by pharmacological inhibition, that insulin down-regulation of Mboat7 is 
dependent on the activation of the PI3Kinase.  
The transcription factors FoxO1 and FoxA2 may represent good candidates to mediate the 
insulin-dependent effect on Mboat7 down-regulation. FoxO1 and FoxA2 are key mediators of insulin 
signaling at transcriptional level, regulating gluconeogenesis and ketogenesis. Akt activation is a  
negative regulator of FoxO1 and FoxA2, determining their phosphorylation, transcriptional inactivation 
and exclusion from the nucleus to cytoplasm and their consequent degradation (19, 90). Interestingly, 
we predicted by bioinformatics algorithms the presence of binding sites for these transcription factor, in 
MBOAT7 promoter, close to the transcription start site of the MBOAT7 main isoform. Supporting a 
role of FoxO1 in mediating insulin-dependent regulation of Mboat7, FoxO1 deletion in wild-type 
primary mouse hepatocytes is similar to that occurred in InsR+/- hepatocytes, it impairs the insulin-
dependent Mboat7 down-regulation, suggesting that FoxO1 is one of the transcription factor required to 
mediate the Mboat7 regulation by insulin. Consistently, the down-regulation  of Mboat7 expression 
observed in InsR+/- genotype was rescued by FoxO1 silencing. These data are consistent with the 
possibility that FoxO1 may regulate Mboat7, although they do not formally prove that this gene is a 
direct target of this transcription factor. Indeed, FoxO1 is able to function both as a coactivator or as a 
corepressor of the transcription of target genes. Specifically, FoxO1 haplo-insufficiency normalized the 
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expression of glucose-6-phosphatase (G6pc) and phosphoenolpyruvate carboxykinase (Pck1),  rate-
limiting enzymes for glycogenolysis and gluconeogenesis, respectively, in insulin resistant mice (i.e. 
InsR+/-), in which FoxO1 activation is predominant (91, 92). In fact, in IR conditions, insulin fails to 
inactivate FoxO1 further inducing hepatic glucose output (23). However, the expression of G6pc and 
Pck1 in InsR+/-FoxO1+/- is comparable to wild-type mice, suggesting that their expression may be 
supported by other FoxO isoforms, such as FoxO3, that is closely related to FoxO1 and it possesses the 
ability to regulate transcription of reporter genes containing insulin response elements from the G6p 
and Pck1 promoters in an insulin-dependent manner (91). As we speculate that FoxO1 is not the only 
mediator of Mboat7 down-regulation by insulin (as FoxO1 silencing did not completely shut down 
Mboat7), we plan to study the also the impact of FoxA2 silencing. Interestingly, FoxA2 binding to the 
Mboat7 promoter was already directly confirmed by a chip-seq peak in hepatocytes, at the same 
position predicted by the bioinformatics software Genomatix. In particular, the hepatic regulation of 
FoxA2 phosphorylation by insulin-stimulated IRS signaling is not impaired in hyperinsulinemia or IR 
states, where FoxA2 is found exclusively in the cytoplasm of hepatocytes, despite the defect in hepatic 
insulin signaling (17, 24). The different regulation of FoxO1 and FoxA2 in IR may be explained by the 
preferential phosphorylation of FoxO1 through insulin–IRS2 signaling, which is impaired in hepatic 
IR, whereas FoxA2 can be phosphorylated by either insulin–IRS1 or insulin–IRS2 signaling (17). 
Moreover, FoxA2 is directly regulated by glucagon, by determining its acetylation at the conserved 
residue Lys259 and promoting its transcriptional activity. Therefore, FoxA2 is transcriptionally active 
in the fasted state (16-18), in which Mboat7 is more expressed.  
Finally, in the third part of this study we sought to confirm in in vivo models whether Mboat7 
down-regulation impact on development of fatty liver in vivo. We showed that acute Mboat7 silencing, 
achieving about 50% down-regulation of protein levels by i.v. injections of MPO antisense 
oligonucleotides for 4 consecutive days resulted in 80% increase in hepatic TG content and in 
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microvesicular steatosis development, without altering circulating glucose, insulin and lipid levels. 
Steatosis development was apparently not explained by altered expression of genes regulating de novo 
lipogenesis or β-oxidation, but was associated with induction of the main hepatocellular fatty acids 
transporters (Fatp1, Fabp1). Supporting the hypothesis that the predisposition to hepatic fat 
accumulation due to Mboat7 down-regulation may be related to an increased FFAs import from the 
circulation into hepatocytes, we found that in the bariatric surgery cohort hepatic FATP1 was inversely 
correlated with MBOAT7 expression. Interestingly, microvesicular steatosis development in Mboat7-
silenced mice was associated with slightly increased circulating FFAs, possibly due to Mboat7 
silencing also in adipose tissue, leading to increased FFAs flux from adipose tissue to the liver. 
However, previous studies did not detect any impact of the MBOAT7 risk alleles on the total amount of 
circulating free fatty acids in humans (60, 61).  
Differently from this previous data, to minimize the confounding effect of obesity we assessed 
also serum FFAs in 72 lean NAFLD patients (with a mean value of BMI of 26), stratified by the 
presence of MBOAT7 T risk allele. In this cohort of patients T2DM and MBOAT7 risk allele were 
independently associated with FFAs circulating concentration, consistently with the hypothesis that in 
NAFLD patients the down-regulation of adipose tissue MBOAT7, caused by the presence of T allele 
may be involved in triggering the phenotype by increasing FFAs availability, then facilitating the 
enhanced uptake of FFAs to the liver, promoting early stages of liver steatosis development. Of note, a 
significant interaction between MBOAT7 genotype and the presence of over-weight has been already 
recorded, in line with the hypothesis that the phenotypic expression of the mutation is triggered by the 
increased flux of fatty acids to the liver (93). We did not highlight differences across genotypes of 
MBOAT7 variant in circulating levels of FFAs in the large cohort of the DHS which includes more 
than 2000 individuals (60), possibly because these subjects have a mean value of BMI of 30, that is 
already considered suggestive of obesity and they have a different ethnicity. 
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Finally, Mboat7 silencing was not directly associated with alterations in the hepatic expression 
of inflammatory cytokines and chemokines (such as Tnf-α and Cxcl10). A possible limitation of this 
study could be the lack of Eicosanoids measurement in sera from Mboat7-silenced mice. Indeed, the 
MBOAT7 reduced activity may influence more promptly the fluctuation of these pro-inflammatory 
mediators (61).  
Another weakness of this study is the absence of Mboat7 KO mice model. In fact, Mboat7 plays 
a crucial role in brain development in mice, since arachidonic acid is the most enriched PUFA in the 
brain and it is involved in multiple aspects of neuronal development and function. Therefore, Mboat7 
KO mice die within a month and show atrophy of the cerebral cortex and hippocampus, disordered 
cortical lamination and neuronal processes and delayed neuronal migration in the cortex (67, 73). A 
possible alternative in order to reproduce Mboat7 reduction may be a liver-specific Mboat7 silenced 
mice model, that we didn’t assessed. This model could be useful to study deeply the effect of the 
reduced activity of Mboat7 on steatosis pathogenesis, further evaluating VLDL exporting processes 
from liver to peripheral tissues. Also a model of full KO in hepatocytes could be intriguing to further 
elucidate that the down-regulation of MBOAT7 is sufficient to predispose to steatosis in hepatocytes. 
However, these models are not representative of the complex cross-talk between the different insulin-
sensitive tissues in presence of Mboat7 reduction. Moreover, we didn’t tested also the in vivo effect of 
acute insulin treatment on several insulin-responsible tissues, confirming the data obtained from 
endogenous production of insulin, due to the refeeding with chow.  
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6. Conclusions  
 
In summary, we found that hyperinsulinemia, a typical feature of metabolic syndrome and post-
prandial conditions, reduces hepatic MBOAT7 expression via increased insulin signaling activation 
through the Insulin receptor - PI3K - FoxO1 pathway. Reduced MBOAT7 then favors in turn hepatic 
fat accumulation. These data suggest that MBOAT7 down-regulation may be implicated in mediating 
the effect of hyperinsulinemia characteristics of the metabolic syndrome in determining the 
development of NAFLD and progressive liver disease in general.  
We speculate that during fasting conditions MBOAT7 is localize specifically in the membranes, 
where it is able to catalyze the desaturation of phospholipids, maintaining their normal fluidity and the 
dynamism, that allows the exchange of the metabolites from the membranes to intracellular 
compartments, such as the mitochondria, thus favoring the β-oxidation processes. Conversely, in 
pathologic state or in post prandial hyperinsulinemia or in patients who carry the T risk allele, 
MBOAT7 is reduced in the membrane fractions, determining the saturation and the immobilization of 
phospholipids, creating a microenvironment that favors TG accumulation and steatosis onset, and 
promoting, by still not characterized mechanisms, the expression of hepatic lipid transporters. 
Moreover, the increased availability of free arachidonic acid may trigger liver inflammation and 
fibrosis, switching simple steatosis to steatohepatitis.  
Future studies will be focused on the evaluation of the insulin-dependent mechanisms of 
MBOAT7 regulation, investigating the role of the transcription factors FoxO1 and/or FoxA2 by 
silencing their expression a) in vivo in experimental models of NAFLD (mice fed MCD and in Lep
ob/ob
 
mice) and b) ex vivo in primary mouse hepatocytes by antisense oligonucleotides. We will plan also to 
investigate whether the effect of MBOAT7 down-regulation on TG accumulation is a cell-autonomous 
property of hepatocytes, by generating a MBOAT7 knock-out cell lines by using the Clustered 
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Regularly Interspaced Short Palindromic Repeats (CRISPR)/CAS9 technology (94). On this purpose, 
we will sough to produce a MBOAT7 deletion in HepG2 cell lines and treat them with low 
concentration of saturated fatty acids, mimicking physiological condition and high concentrations, 
representative of pathological condition, in order to understand the exact mechanisms through which 
MBOAT7 down-regulation induces steatosis development, and the effect of MBOAT7 down-
regulation on specific fatty acids transporters.  
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